Cigna at 11 Times Earnings: Most of the Business Is Not Insurance

Cigna trades around $275.28 as I write this, at 11.4 times trailing earnings. Its own five-year average is 16.8. That is a 32% discount to itself, and anyone who assumes the market is simply being lazy should look at the second-quarter revenue split first.

In the quarter that ended in June, Cigna reported total revenue of about $71.7 billion. Of that, $61.5 billion came from Evernorth Health Services and $11.8 billion from Cigna Healthcare, the insurance arm, according to the company’s second-quarter 2026 results. Those two add to more than the total because of eliminations between them. By my arithmetic Evernorth is about 86% of the top line and the insurer about 16%.

My view: the stock is not a health insurer priced at an insurer’s multiple, and that is the whole story. The cheap multiple describes a pharmacy benefit company with a small, growing insurer attached, and the real question is whether the pharmacy side is getting squeezed harder than the earnings suggest.

What Evernorth actually earns

Revenue tells you volume. It does not tell you profit. Evernorth handles pharmacy benefits, specialty drugs and care services, which means it moves enormous quantities of drugs and keeps a thin slice of each dollar. That explains why the trailing price-to-sales ratio is only 0.3, against a five-year average of 0.4, and why revenue of roughly $71 billion in a quarter does not turn into a huge profit.

The company’s own split shows the tension. In the second quarter, Evernorth revenue rose 6%, but its adjusted pre-tax income from operations fell 2%. Inside it, pharmacy benefit services grew adjusted revenue 8% while adjusted pre-tax income dropped 27%. The release attributes that to client-focused initiatives, including large contract renewals. Specialty and care services went the other way: revenue up 4%, income up 22%.

So the piece of the business that carries most of the volume is the piece where profit per dollar is shrinking. I read that as the market’s fear made concrete. A 27% decline in pharmacy benefit income is the number behind the multiple.

Compare Cigna Healthcare. Revenue was up 10%, to $11.8 billion, and pre-tax adjusted earnings rose 17% to $1.3 billion. On $11.8 billion of revenue, that is a margin above 10%, while the whole company’s operating margin is around 3%. The small part of the company is the more profitable one.

Growth is settling near a normal rate

Annual revenue climbed from $179.4 billion in 2022 to $194.1 billion in 2023, then $246.1 billion in 2024 and $273.9 billion in 2025. The latest year grew 11%. The most recent quarter grew about 7% from the prior year, and the sequential change is 5%.

I would not read the 27% jump in 2024 as organic strength. Revenue in a pass-through business swells when contracts, drug prices or drug mix change, and those shifts inflate the top line without adding much margin. The data I have does not say why the growth was so fast, so I leave the reason open.

Profit is the more useful line. Trailing net income is $6.3 billion, up from $3.8 billion the year before, and the net margin is only about 2%. Gross margin dipped from 10.2% to 9.0%. A company that moves more revenue and keeps a lower share of each dollar is what a pass-through model does when it wins volume by cutting price.

A multiple this low asks a question

An 11.4 times multiple means the market will pay $11.40 for each dollar of trailing profit. The forward P/E is 10.5. Trailing EPS is $24.18 and forward EPS is $26.30, an implied 9% increase.

One caution. The company’s guidance is stated in adjusted EPS, and management raised the 2026 outlook to at least $30.45. That figure is higher than the $24.18 of trailing earnings because adjusted numbers exclude items such as amortization of acquired intangibles. Compared with $30.45, the stock at $275.28 trades at under 9.1 times adjusted guidance. Under either measure the shares are cheap. I would still use the lower, unadjusted figure when judging quality, because that is closer to what shareholders’ accounts recognize.

A low multiple often means investors expect earnings to fall. I looked for evidence of that. The evidence points the other way: net income rose from $3.8 billion to $6.3 billion, the second-quarter profit was $1.7 billion, up more than 8%, and the outlook was raised. What the market is really pricing is a decline in future margin, not present earnings.

That is a coherent bet. If pharmacy benefit contracts keep being renegotiated toward lower fees, the profit of the largest segment shrinks even as revenue grows. Regulators and large employers push that way. I do not think the market is stupid to worry.

Comparing cheap to cheap

I made a similar case in a post on Medtronic against its own history, where a multiple of 22.7 was a discount because the company had traded higher for years. Cigna’s discount is deeper in percentage terms. The comparison is unfair in one way: Medtronic makes devices, and Cigna’s earnings depend on contracts that can be repriced.

A different contrast is Alphabet at 20 times earnings, where the discount was against a peer group and the business kept growing quickly. Cigna’s growth is closer to 5% to 10% in revenue, and profit growth is uneven. The lower multiple is earned.

The table shows the figures behind my argument.

Metric	Value	Context
Price	$275.28	52-week range $234 to $308
P/E (TTM / forward)	11.4 / 10.5	five-year average 16.8
Trailing / forward EPS	$24.18 / $26.30	2026 adjusted outlook: at least $30.45
Evernorth Q2 revenue	$61.5 billion	pharmacy benefit income down 27%
Cigna Healthcare Q2 revenue	$11.8 billion	pre-tax adjusted earnings up 17%
Dividend	$6.14 a share	yield 2.23%

The payout is small, and that helps

The trailing dividend is $6.14 per share, a yield of 2.23%. Against $24.18 of trailing EPS, the payout ratio is about 25%. That is low. It means the dividend is not the reason to own the stock, and it also means the board has room to raise it or to buy back shares when the price is depressed.

At a market value of $72.7 billion, even a modest buyback retires a visible share of the company each year. I like buybacks when they happen below five-year average multiples, because the same dollar buys more earnings. That is the case here. I cannot verify how much the company plans to repurchase, so I leave the amount out.

What the analysts and the tape say

Sixteen analysts follow the stock, and 69% rate it a buy. The average target is $338, which is 23% above the price. The low target of $290 sits 5% above the price and the high of $381 is 38% above. Nobody on the list is at or below today’s price, which is unusual and makes me suspicious of the consensus more than reassured.

Short interest is 2.4% of shares. The price has recovered to 10.8% below its 52-week high of $308, and it sits 18% above the low of $234.

Earnings days have moved the stock about 6.4% on average. On July 30, when the company raised guidance, the shares moved -3.0%. A raise that produces a drop tells me investors are focused on the quality of the growth, not the headline. My own read is that the market wants to see the pharmacy benefit margin stop falling before it pays up.

Where I could be wrong

The strongest argument against me is that the discount is deserved and will stay. Pharmacy benefit managers face pressure from clients, regulators and public scrutiny of how they are paid. If the 27% decline in pharmacy benefit income repeats for several quarters, a multiple of 11 will look generous, and the average of 16.8 will turn out to have been an artifact of a friendlier period.

The argument for me is that the other pieces are healthy. Specialty and care services earned 22% more, and Cigna Healthcare earned 17% more. If those two grow at that pace while pharmacy benefits stabilize, adjusted earnings can rise beyond guidance and the multiple has room to move back toward its history.

Neither camp needs to be right for me to say something narrow: the price already includes a fair amount of pessimism. The stock at $275.28 does not need good news to work. It needs the news to stop getting worse in one segment.

The line I would follow next

I would follow one number, and it is pharmacy benefit services income. If the decline narrows from 27% to something in single digits over the next two reports, I would call the thesis intact and the discount an opportunity. If it deepens beyond 30%, I would stop calling it cheap and start calling it priced for a shrinking business.

Since a report day can bring a drop of 6% or more, based on the average move, I would not plan around a single entry date. Spreading purchases across several weeks, or waiting until after the next results on the calendar, avoids paying for a surprise on either side.

Analysis and opinion only, not investment advice. Figures come from Cigna’s filings on SEC EDGAR and its investor site, plus its second-quarter 2026 results; valuation multiples are approximate and were checked on September 22, 2026.